Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure relates to prostate specific membrane antigen (PSMA) targeted compounds conjugated to near-infra red (NIR) dyes and methods for a method for synthesizing a compound of the formula:
Core Innovation
The disclosure describes PSMA-targeted near-infrared dye conjugates and methods for synthesizing formula-defined compounds and dye-containing products through sequential reactions; [procedural detail omitted for safety]. The conjugates comprise a DUPA-linker-amino-acid-dye architecture, including tyrosine-containing linkers and conjugates such as OTL78 and DUPA-EAOA-tyrosine-S0456, for imaging PSMA-expressing tumors. The described synthesis methods encompass non-isotopic compounds where n is selected from 0, 1, 2, 3, or 4, as well as isotopically labeled forms.
Analytical characterization of the synthesized compounds includes diode-array chromatograms, UV-visible traces, and mass spectra reporting mass-to-charge signals for characterization and purification. Preclinical evaluations report approximately 1 nM PSMA-binding affinity, selective uptake in PSMA-positive 22Rv1 tumors, negligible uptake in PSMA-negative PC3 tumors, and tumor retention for at least 24 hours. Because the background section is omitted in the supplied material, the specific problem being solved is not explicitly described in patent.
Claims Coverage
The claims identify three independent claims, claims 1, 3, and 4, covering three inventive features directed to sequential synthesis methods for formula-defined compounds, an isotopic form, and dye-containing reaction products.
Synthesis of a compound with specified substituents followed by dye attachment
Independent claim 1 covers a method for synthesizing a compound with specified ionic forms or counterion choices and n selected from 0, 1, 2, 3, or 4, followed by reaction with a dye compound; [procedural detail omitted for safety].
Synthesis of an isotopic form followed by dye attachment
Independent claim 3 covers a method for synthesizing an isotopic form of a compound comprising one or more recited hydrogen or carbon isotopes, followed by reaction with an isotopic form of a dye compound; [procedural detail omitted for safety].
Synthesis of a compound with a specified n range followed by dye attachment
Independent claim 4 covers a method for synthesizing a compound of a specified formula wherein n is 0, 1, 2, 3, or 4, followed by reaction of the resulting compound with a dye compound; [procedural detail omitted for safety].
The three independent claims cover sequential synthesis methods for PSMA-targeting dye conjugates, encompassing non-isotopic compounds with defined substituents, isotopic forms, and compounds defined by a specified range of n.
Stated Advantages
Brighter fluorescence and improved tumor-to-background contrast, with variations in linker length, amino-acid identity, and charge improving fluorescence, tumor accumulation, clearance, and contrast.
Detection of smaller or deeper lesions.
Reduced dose requirements.
Cleaner surgical margins.
Approximately 1 nM PSMA-binding affinity and selective uptake in PSMA-positive tumors, with negligible uptake in PSMA-negative tumors or other tissues.
Tumor retention for at least 24 hours.
Documented Applications
Imaging and diagnostic evaluation of PSMA-expressing tumors, including prostate cancer.
Image-guided resection and fluorescence-guided surgery for PSMA-expressing tumors.
Synthesis, characterization, and purification of the claimed dye-related compounds and isotopic forms.
In vivo fluorescence imaging and preclinical evaluation involving 22Rv1 prostate cancer cells, PSMA-positive tumor xenografts, and PC3 prostate tumors, with fluorescent signal observed at 8, 24, and 48 hours.
Interested in licensing this patent?